RxDoctor Payments Data

Lisa Doom-Anderson

Family · Sioux Falls, SDNPI 1972932374

Payments from drug & device makers

$595in general payments, 2019–2025

Across 21 payments — averaging $28.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Heartflow, Inc.$167
  • Novartis$86
  • Actelion Pharmaceuticals US, Inc.$82
  • Medtronic$48
  • Abiomed$38
  • E.r. Squibb & Sons, L.L.C.$32
  • plus $142 from 7 others

What the payments were for

  • Food & beverage$51386%
  • Education$8214%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$595 in reported general payments places this provider in the 65th percentile of 588 family providers in South Dakota.

See all family providers in South Dakota

Medicare billing

Part B allowed, 2024
$96,383
Medicare patients
1,012
Services billed
1,941

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban317$302,415
JardianceEmpagliflozin199$196,368
FarxigaDapagliflozin Propanediol174$147,320
EntrestoSacubitril/Valsartan117$135,019
XareltoRivaroxaban140$129,279
Repatha SureclickEvolocumab155$88,542
Praluent PenAlirocumab98$48,086
BrilintaTicagrelor12$13,901
Rosuvastatin Calcium821$11,257
Ezetimibe406$10,627
Ranolazine ErRanolazine69$10,040
Metoprolol Succinate546$7,709
Repatha SyringeEvolocumab11$5,462
Carvedilol737$4,567
Atorvastatin Calcium440$4,302

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$302,415317 claims
Boehringer IngelheimJardiance$15$196,368199 claims
NovartisEntresto$86$135,019117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 588 family providers in South Dakota.

Other family in Sioux Falls

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →